Axsome TherapeuticsAXSM
AXSM
About: Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Employees: 589
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 14 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
61% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 38
49% more call options, than puts
Call options by funds: $181M | Put options by funds: $121M
38% more funds holding in top 10
Funds holding in top 10: 8 [Q3] → 11 (+3) [Q4]
5% more funds holding
Funds holding: 274 [Q3] → 288 (+14) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 90
1.48% less ownership
Funds ownership: 79.74% [Q3] → 78.26% (-1.48%) [Q4]
9% less capital invested
Capital invested by funds: $3.44B [Q3] → $3.14B (-$293M) [Q4]
Research analyst outlook
14 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$143
27%
upside
Avg. target
$176
57%
upside
High target
$216
92%
upside
14 analyst ratings
14 positive
100%
0 neutral
0%
0 negative
0%
RBC Capital Leonid Timashev 21% 1-year accuracy 9 / 42 met price target | 72%upside $193 | Outperform Maintained | 29 Apr 2025 |
Jefferies Andrew Tsai 17% 1-year accuracy 1 / 6 met price target | 78%upside $200 | Buy Initiated | 7 Apr 2025 |
HC Wainwright & Co. Raghuram Selvaraju 38% 1-year accuracy 125 / 331 met price target | 78%upside $200 | Buy Reiterated | 3 Apr 2025 |
Needham Ami Fadia 22% 1-year accuracy 35 / 160 met price target | 36%upside $153 | Buy Reiterated | 1 Apr 2025 |
Mizuho Graig Suvannavejh 32% 1-year accuracy 7 / 22 met price target | 92%upside $216 | Outperform Maintained | 27 Mar 2025 |
Financial journalist opinion
Based on 13 articles about AXSM published over the past 30 days
Negative
Zacks Investment Research
2 days ago
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
1 week ago
Axsome Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in four upcoming investor conferences in May:
Neutral
GlobeNewsWire
2 weeks ago
Kuehn Law Encourages Investors of Five Below, Inc. to Contact Law Firm
NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Five Below, Inc. (NASDAQ: FIVE) breached their fiduciary duties to shareholders.
Neutral
GlobeNewsWire
2 weeks ago
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders.
Neutral
GlobeNewsWire
2 weeks ago
Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to Contact Law Firm
NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Axsome Therapeutics, Inc. (NASDAQ: AXSM) breached their fiduciary duties to shareholders.
Positive
Zacks Investment Research
2 weeks ago
Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last?
Axsome (AXSM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Neutral
PRNewsWire
3 weeks ago
Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to Contact Law Firm
NEW YORK , April 8, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Axsome Therapeutics, Inc. (NASDAQ: AXSM) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Axsome caused the company to misrepresent or fail to disclose (i) Axsome's chemistry, manufacturing, and control ("CMC") practices were deficient with respect to AXS-07 and its manufacturing process; (ii) as a result, Axsome was unlikely to submit the AXS-07 NDA on its initially represented timeline; (iii) the foregoing CMC issues remained unresolved at the time that the FDA reviewed the AXS-07 NDA; (iv) accordingly, the FDA was unlikely to approve the AXS-07 NDA; (v) as a result of all the foregoing, Axsome had overstated AXS-07's regulatory and commercial prospects; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
Neutral
GlobeNewsWire
3 weeks ago
Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the first quarter of 2025 on Monday, May 5, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update.
Neutral
GlobeNewsWire
3 weeks ago
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting
Late-breaking oral presentation of results from the positive pivotal ACCORD-2 Phase 3 trial of AXS-05 in Alzheimer's disease agitation
Negative
Zacks Investment Research
4 weeks ago
AXSM Stock Down on Top-Line Data From Depression Study on Solriamfetol
Axsome's phase III PARADIGM study evaluating solriamfetol in major depressive disorder fails to show a statistically significant change in the primary endpoint.
Charts implemented using Lightweight Charts™